Taylor A.Goodspeed


New York + 1.212.326.3450

Taylor Goodspeed focuses on regulatory, compliance, and civil litigation matters involving the health care industry. She counsels and defends hospitals, health systems, life sciences companies, and other health care entities in civil fraud and abuse investigations and litigation, particularly under the civil False Claims Act (FCA) and similar state laws. She also helps steer clients through high-profile investigations from federal and state agencies. She routinely provides strategic counsel and guidance to digital health and medical technology companies in navigating the current health care regulatory scheme.

Taylor worked closely with the in-house legal team at a global biopharmaceutical company while on secondment in its litigation and government investigations group. During that time, she managed a wide variety of matters including civil litigation, interactions with enforcement authorities, and internal investigations across the globe.

Taylor has also counseled health systems and emerging companies on federal and state anti-kickback statutes, federal and state referral prohibitions, licensure requirements, and state corporate practice of medicine provisions. Prior to joining Jones Day, Taylor coauthored multiple publications on public attitudes towards noninvasive prenatal testing, such as cell-free fetal DNA technology.

Taylor maintains an active pro bono practice, serving on Jones Day's Anti-Human Trafficking Committee and on the American Hospital Association's (AHA) Human Trafficking Advisory Committee. She has also presented widely on the Firm's pro bono anti-trafficking efforts.

Taylor is currently serving her second term as a member of the Women's Leadership Council for the American Health Law Association (AHLA).


  • Nurx merges with Thirty MadisonJones Day provided healthcare and data privacy counsel to Nurx in connection with its merger with Thirty Madison, a leading digital healthcare company operating across the U.S.
  • Maven Clinic receives historic Series D investment fundingJones Day advised Maven Clinic as health regulatory counsel in its $110 million Series D investment round, co-led by Dragoneer Investment Group and Lux Capital.
  • MDLIVE sells company to Cigna's EvernorthJones Day advised MDLIVE in its sale to Cigna's health services subsidiary Evernorth.
  • Digital health companies, specialty hospitals, and health systems maintain compliance with multistate requirements through 50-state surveyJones Day is representing digital health companies, specialty hospitals, and health systems in maintaining compliance with multistate requirements through a regularly updated, extensive 50-state survey on state laws and regulations applicable to telehealth activities of physicians and other health care professionals including licensing, establishing patient relationships, provider-to-provider consulting, supervision and delegation among providers, and prescribing and treatment standards.
  • Drug manufacturer intervenes in litigation to defend Section 340B drug pricingJones Day represents a drug manufacturer in litigation challenging its discounted drug pricing practices under Section 340B of the Public Health Service Act.
  • Several digital health companies successfully close state regulatory board investigationsJones Day successfully represented several digital health companies and their affiliated physicians in responding to state medical board investigations regarding the provision of clinical services including certain laboratory tests and prescription drug orders.
  • Academic medical center considers multi-state second opinion servicesJones Day provided strategic health regulatory guidance to a preeminent academic medical center in connection with their multi-state second opinion and telehealth programs.
  • Innovative primary care clinic expands platform and offeringsJones Day is providing on-going strategic regulatory guidance and advice to a membership-based primary care practice in connection with telemedicine, COVID-19 response, and general health care regulatory and compliance matters.
  • Digital health company expands telehealth programming in response to the COVID-19 public health crisisJones Day represented a digital health company in the expansion of their telehealth programming in response to the COVID-19 public health crisis.
  • Emerging specialty service launches telehealth platformJones Day advised an emerging direct to consumer telehealth organization focusing on teledermatology with terms of service, privacy policy, and telehealth consent for launching operations in several states across the U.S.
  • National digital health company launches government partnershipJones Day advised a large digital health company with multi-clinical services in negotiating a partnership with a state government program to provide telehealth and telemedicine consults during the COVID-19 state of emergency.
  • Durable medical equipment company defends against False Claims Act qui tam lawsuitJones Day is representing a durable medical equipment company in connection with a False Claims Act investigation alleging violation of state best price requirements.
  • Hospital system defends against novel federal and state False Claims Act qui tam lawsuitsJones Day is representing a hospital system in connection with two novel federal and state False Claims Act matters alleging improper arrangements with Medicaid managed health care plans.
  • Large digital health company grows operations across U.S.Jones Day advised a large digital health company in expanding operations throughout multiple states in the U.S. and in responding to several state regulator inquiries regarding its operations.